FDA Clears a Six-Month Trelstar Formulation for the Palliative Treatment of Advanced Prostate Cancer
Watson Pharmaceuticals announced that it has received approval from the FDA for its new six-month intramuscular formulation, Trelstar, a (triptorelin pamoate for injectable suspension) 22.5 mg. Trelstar 22.5 mg is a gonadotropin releasing hormone (GnRH) [...]
Coffee, Coffee – I Need My Cup of Coffee!
Many of us once considered drinking coffee nothing but a bad habit, but now it looks as if drinking coffee is actually a good thing for us. Researchers are finding more and more benefits from [...]
Light the White House in Blue Lights
Dear President Obama, Prostate cancer will hit one in every six American men. This means that one in every six families will also be affected by prostate cancer. Prostate cancer is the second biggest cancer [...]
On The Horizon – PROSTVAC™, The Next Break Out-Prostate Cancer Vaccine To Watch
Bavarian Nordic (B/N) is in the process of testing what might be the next prostate cancer vaccine to become available. They have successfully completed a phase II trial of 125 men with metastatic prostate cancer. [...]
US FDA Reviewing the Safety of LHRH Agonists – ADT with Advanced Prostate Cancer
Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some [...]
Analyzing Prostate Cancer Using the CTC-Chip – Insights into the Prognosis of Recurrent Prostate Cancer
Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at [...]